Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Slides:

Advertisements

Similar presentations

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Advertisements

¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Non–ST-Segment Elevation Acute Coronary.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Benefit of Early Invasive Therapy in Acute Coronary.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.

From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel.

The patient with atrial fibrillation who needs PCI

Figure 1 Ischaemic endpoints

Oral Anticoagulation and Preventing Stent Thrombosis

Glenn N. Levine et al. JACC 2016;68:

Glenn N. Levine et al. JACC 2016;68:

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Pharmacodynamic comparison of crushed versus integral

Figure 1 Mechanism of thrombus formation during ST-segment

Nat. Rev. Cardiol. doi: /nrcardio

NOACS: Emerging data in ACS/IHD

Nat. Rev. Cardiol. doi: /nrcardio

AF and PCI in Practice.

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

Nat. Rev. Cardiol. doi: /nrcardio

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

George E. Kikano, MD, Marie T. Brown, MD Mayo Clinic Proceedings

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 PCI strategies in patients with STEMI and multivessel disease

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Manual thrombus aspiration

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Nat. Rev. Cardiol. doi: /nrcardio

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Figure 2 Absolute difference in seasonal peak

Figure 4 Observational studies on multiple treatment strategies

Mancini JG, et al. Am J Cardiol.

Nat. Rev. Cardiol. doi: /nrcardio

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Figure 1 Ischaemic conditioning

Potential mechanisms whereby statins may reduce the risk of stroke

Nat. Rev. Cardiol. doi: /nrcardio

Factor Xa Inhibitors in Coronary Artery Disease

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Electrocardiogram patterns associated with Brugada syndrome

Figure 1 Platelet receptors and available pharmaceutical options

Efficacy and Safety of Fondaparinux in Elderly Patients With ST-Segment Elevation Myocardial Infarction: Data From the OASIS 6 Trial Ron J.G. Peters,

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

Section C: Clinical trial update: Oral antiplatelet therapy

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Presentation transcript:

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial infarction (STEMI) subgroups of major clinical trials on novel oral antithrombotic agents Figure 3 | Ischaemic outcomes in the ST-segment elevation myocardial infarction (STEMI) subgroups of major clinical trials on novel oral antithrombotic agents. Risk reduction of novel antithrombotic agents versus dual antiplatelet therapy with aspirin and clopidogrel in post-hoc analyses on the STEMI subgroups of clinical trials performed in patients with acute coronary syndromes. Major adverse cardiovascular events are the primary end point of each trial. *Results are reported for the comparison between rivaroxaban 2.5 mg versus placebo. Franchi, F. et al. (2017) Antithrombotic therapy for patients with STEMI undergoing primary PCI Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.18